1. Home
  2. PRTC vs MAGN Comparison

PRTC vs MAGN Comparison

Compare PRTC & MAGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTC
  • MAGN
  • Stock Information
  • Founded
  • PRTC 2015
  • MAGN 1864
  • Country
  • PRTC United States
  • MAGN United States
  • Employees
  • PRTC N/A
  • MAGN N/A
  • Industry
  • PRTC Biotechnology: Pharmaceutical Preparations
  • MAGN Paper
  • Sector
  • PRTC Health Care
  • MAGN Basic Materials
  • Exchange
  • PRTC Nasdaq
  • MAGN Nasdaq
  • Market Cap
  • PRTC 435.0M
  • MAGN 416.2M
  • IPO Year
  • PRTC N/A
  • MAGN N/A
  • Fundamental
  • Price
  • PRTC $17.26
  • MAGN $8.97
  • Analyst Decision
  • PRTC
  • MAGN Hold
  • Analyst Count
  • PRTC 0
  • MAGN 1
  • Target Price
  • PRTC N/A
  • MAGN $12.00
  • AVG Volume (30 Days)
  • PRTC 3.7K
  • MAGN 856.4K
  • Earning Date
  • PRTC 08-28-2025
  • MAGN 11-15-2025
  • Dividend Yield
  • PRTC N/A
  • MAGN N/A
  • EPS Growth
  • PRTC N/A
  • MAGN N/A
  • EPS
  • PRTC 0.20
  • MAGN N/A
  • Revenue
  • PRTC $6,391,000.00
  • MAGN $2,919,000,000.00
  • Revenue This Year
  • PRTC N/A
  • MAGN $49.20
  • Revenue Next Year
  • PRTC N/A
  • MAGN $5.03
  • P/E Ratio
  • PRTC $8.54
  • MAGN N/A
  • Revenue Growth
  • PRTC 1265.60
  • MAGN 34.21
  • 52 Week Low
  • PRTC $13.30
  • MAGN $9.27
  • 52 Week High
  • PRTC $24.99
  • MAGN $26.78
  • Technical
  • Relative Strength Index (RSI)
  • PRTC 46.41
  • MAGN 28.93
  • Support Level
  • PRTC $17.63
  • MAGN $9.94
  • Resistance Level
  • PRTC $18.17
  • MAGN $10.73
  • Average True Range (ATR)
  • PRTC 0.21
  • MAGN 0.59
  • MACD
  • PRTC -0.07
  • MAGN -0.20
  • Stochastic Oscillator
  • PRTC 15.66
  • MAGN 0.47

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

About MAGN Magnera Corporation Common Stock

Magnera Corp formerly Glatfelter Corporation manufactures and sells a variety of paper and fiber products. The company's reportable segments are; Composite Fibers, Spunlace. and Airlaid Materials. The Airlaid Materials segment which is also its key revenue generating segment, is a supplier of cellulose-based airlaid nonwoven materials used to manufacture consumer products for end-user markets. The Airlaid Materials segment produces materials used in feminine hygiene, specialty wipes, tabletop, home care, and other consumables. Geographically, the company derives majority of its revenue from Americas and rest from Europe, Middle East, Africa and Asia Pacific markets.

Share on Social Networks: